\n
Novartis\u2019 present technique could be traced again to\u00a0October 2023, when the Swiss pharma accomplished the spin-off of Sandoz, its generics and biosimilars enterprise. The corporate\u00a0described\u00a0the transfer because the completion of a strategic transformation\u00a0into\u00a0a centered modern medicines firm,\u00a0whereas chief govt officer (CEO) Vas Narasimhan\u00a0stated it allowed Novartis to \u201cabsolutely deal with high-value modern medicines.\u201d\u00a0<\/p>\n
Novartis says it’s concentrating on 4 core therapeutic areas: cardiovascular, renal and metabolic ailments, oncology, immunology, and neuroscience, supported by expertise platforms together with xRNA, radioligand remedy, and gene and cell remedy.\u00a0<\/p>\n
On the similar time, within the first quarter of 2026, generic competitors hit a number of older merchandise: Entresto gross sales fell\u00a042%, Promacta 66%, and Tasigna 59%, partly offset by progress from newer medicines together with Kisqali and Pluvicto. Reuters\u00a0described\u00a0this as Novartis navigating its most extreme interval of patent expiries, led by Entresto, which accounted for 14% of gross sales the earlier yr.\u00a0<\/p>\n
Regardless of this powerful time, Novartis has been\u00a0spending closely\u00a0to strengthen the following era of its pipeline. Current offers embody the acquisition of Avidity Biosciences to broaden its xRNA and late-stage neuroscience pipeline, the acquisition of Tourmaline Bio so as to add the anti-IL-6 antibody pacibekitug in atherosclerotic heart problems, and continued funding in radioligand remedy, which Novartis described in its 2025 annual report as one in every of its market-leading superior expertise platforms.\u00a0<\/p>\n
Novartis: a\u00a0story about focus\u00a0\u00a0<\/h2>\n
Novartis was created in 1996 by way of the merger of Ciba-Geigy and Sandoz, bringing collectively companies with roots in chemical compounds, prescription drugs and broader healthcare. Novartis didn’t start because the centered modern medicines firm it’s at present; it was constructed from a much wider industrial and healthcare base.\u00a0<\/p>\n
In 2015, Novartis mixed its shopper healthcare enterprise with GSK\u2019s in a three way partnership, and three years later, it\u00a0offered\u00a0its\u00a036.5% stake\u00a0to GSK for\u00a0$13 billion, ending its participation in shopper well being. Novartis described that sale as a part of its portfolio transformation and a transfer to deal with strategic priorities.\u00a0<\/p>\n
The identical logic utilized to eye care, when in 2019, Novartis\u00a0spun off\u00a0Alcon\u00a0as\u00a0a separate firm. On the time, Novartis stated the transaction would enable it to focus capital allocation and administration consideration on medicines, whereas giving the group a monetary profile nearer to pharmaceutical friends, together with greater margins.\u00a0<\/p>\n
Lastly, in October 2023, Novartis\u00a0accomplished\u00a0the spin-off of Sandoz, its\u00a0generics and biosimilars enterprise.\u00a0Novartis framed the transfer because the completion of its strategic transformation right into a centered modern medicines\u00a0firm.\u00a0<\/p>\n
Shopper well being, eye care and generics every had completely different economics, progress\u00a0profiles\u00a0and administration calls for. Eradicating them left Novartis with a cleaner\u00a0pipeline technique:\u00a0allocate\u00a0capital and\u00a0deal with\u00a0analysis and growth (R&D).\u00a0<\/p>\n
The problem: patent lapse and generics\u00a0<\/h2>\n
The corporate entered 2026 with a transparent strategic profile, but additionally with a visual income downside.\u00a0In its\u00a0Q1 2026 outcomes, Novartis stated internet gross sales declined 5%, with the primary stress coming from three older merchandise: Entresto, whose U.S. generics entered\u00a0the market\u00a0in Q3 2025, and\u00a0Tasigna\u00a0and Promacta, which confronted U.S. generics from Q2 2025.\u00a0<\/p>\n
Probably the most\u00a0vital is Entresto, Novartis\u2019 coronary heart failure drugs and one of many firm\u2019s\u00a0largest merchandise. In 2025, Entresto\u00a0generated\u00a0$7.75 billion in gross sales, making it Novartis\u2019 largest-selling drugs forward of Cosentyx and Kisqali.\u00a0However by the primary quarter of 2026, Entresto gross sales\u00a0fell\u00a042%\u00a0yr on\u00a0yr to $1.3 billion. Promacta, utilized in blood problems, fell 66% to $184 million, whereas Tasigna, an older most cancers remedy, fell 59% to $155 million. Novartis stated generic competitors negatively affected all three merchandise, partly offset by robust progress from newer medicines together with Kisqali, Pluvicto, Kesimpta, Scemblix and Leqvio.\u00a0<\/p>\n
Novartis\u2019 present\u00a0progress\u00a0engines, together with Cosentyx, Kisqali and Kesimpta, are nonetheless increasing, however\u00a0they too will ultimately mature and face their very own lifecycle questions. Reuters reported that Cosentyx, Kesimpta and Kisqali are anticipated to lose patent safety within the early 2030s, which implies Novartis is already making an attempt to construct the expansion layer after the present one.\u00a0\u00a0<\/p>\n
Nevertheless,\u00a0Novartis just isn’t presenting 2026 as a disaster yr and reaffirmed its full-year steering in Q1 2026, at the same time as gross sales and core working earnings declined, pointing to\u00a0robust progress\u00a0from precedence manufacturers. That’s the context by which Novartis\u2019 dealmaking must be interpreted.\u00a0\u00a0<\/p>\n
Constructing Novartis\u2019 pipeline round 4 pillars\u00a0<\/h2>\n
Novartis\u2019 current dealmaking appears broad, however it isn’t random. Many of the offers map onto the 4 therapeutic areas the corporate says outline its enterprise: cardiovascular-renal-metabolic, oncology,\u00a0neuroscience\u00a0and immunology. Novartis has additionally stated these areas are supported by expertise platforms together with radioligand remedy and\u00a0xRNA, which helps clarify why most of the offers should not simply product acquisitions however functionality acquisitions.\u00a0<\/p>\n
Novartis cardiovascular pipeline: from Entresto to prevention, irritation and RNA\u00a0<\/h3>\n
Heart problems stays central to Novartis, at the same time as Entresto loses exclusivity. Novartis\u2019s newer cardiovascular technique appears broader than merely changing one coronary heart failure drug with one other: lipid decreasing,\u00a0thrombosis prevention, irritation and RNA-based approaches.\u00a0<\/p>\n
Leqvio is a component of that cardiovascular pipeline. The siRNA drugs, used to decrease LDL ldl cholesterol, provides Novartis a cardiovascular asset constructed round long-acting RNA interference. In 2025, Leqvio gross sales reached $1.24 billion, up 73%, and in Q1 2026 gross sales grew 69%, with Novartis pointing to robust progress\u00a0in China.\u00a0<\/p>\n
The Anthos acquisition provides one other layer to\u00a0the technique. Novartis\u00a0agreed\u00a0to purchase Anthos for $925 million upfront, gaining abelacimab, a part 3 Issue XI inhibitor being developed for prevention of stroke and systemic embolism in sufferers with atrial fibrillation. That strikes Novartis right into a next-generation anticoagulation house,\u00a0the place corporations try to scale back clotting threat with out reproducing the bleeding burden of older anticoagulants.\u00a0<\/p>\n
Tourmaline Bio pushes the technique towards irritation in cardiovascular\u00a0illness.\u00a0The $1.4 billion\u00a0acquisition\u00a0provides Novartis pacibekitug, an anti-IL-6 antibody being developed for atherosclerotic heart problems (ASCVD). Novartis\u00a0stated\u00a0the deal\u00a0complemented\u00a0its cardiovascular pipeline,\u00a0with a\u00a0part 3-ready\u00a0candidate\u00a0concentrating on\u00a0systemic irritation in ASCVD.\u00a0<\/p>\n
Novartis aso\u00a0signed\u00a0a licensing and choices settlement value as much as $5.2 billion with Argo for cardiovascular siRNA candidates, together with a mid-stage program for elevated blood lipids and choices on further candidates addressing cholesterol-related illness drivers.\u00a0<\/p>\n
The Novartis cardiovascular story\u00a0doesn\u2019t\u00a0finish with Entresto\u2019s patent expiry,\u00a0and\u00a0the pipeline now appears\u00a0extra stratified.\u00a0<\/p>\n
Novartis oncology technique: focus round progress manufacturers and differentiated modalities\u00a0<\/h3>\n
Novartis can be nonetheless closely dedicated to oncology.\u00a0In 2025,\u00a0Kisqali, the corporate\u2019s industrial anchor, generated\u00a0$4.78 billion\u00a0in gross sales, up 57%, and in Q1 2026 it grew 55% to\u00a0$1.52 billion, helped by momentum in early breast most cancers and metastatic breast most cancers.\u00a0<\/p>\n
Then there’s Pluvicto; past a prostate most cancers drug, it’s the clearest industrial take a look at of Novartis\u2019 radioligand remedy\u00a0(RLT)\u00a0technique.\u00a0In Q1 2026,\u00a0Pluvicto\u00a0gross sales grew 70% to $642 million, pushed by demand in pre-taxane metastatic castration-resistant prostate most cancers within the U.S. and entry enlargement exterior the U.S.\u00a0<\/p>\n
The Mariana Oncology\u00a0acquisition\u00a0again in 2024 exhibits how Novartis is making an attempt to deepen that place. Mariana introduced a portfolio of preclinical radioligand remedy packages throughout strong tumors, together with areas reminiscent of breast, prostate,\u00a0and lung most cancers. Novartis framed the deal\u00a0as a method to\u00a0strengthen its RLT pipeline and develop next-generation most cancers remedies.\u00a0<\/p>\n
Novartis is inserting heavier emphasis on areas the place it has both\u00a0a powerful progress\u00a0model, reminiscent of Kisqali, or a expertise platform that might generate a number of merchandise\u00a0\u2014\u00a0radioligand remedy.\u00a0<\/p>\n
Novartis neuroscience pipeline: rebuilding by way of supply and RNA capabilities\u00a0<\/h3>\n
Novartis\u2019 current strikes recommend a broader effort past Alzheimer\u2019s to rebuild the neuroscience pipeline by way of applied sciences that may attain troublesome tissues or troublesome biology.\u00a0<\/p>\n
The biggest instance is Avidity Biosciences. Novartis\u00a0accomplished\u00a0the acquisition earlier this yr in February, including Avidity\u2019s antibody-oligonucleotide conjugate platform and three late-stage neuromuscular packages.\u00a0<\/p>\n
There may be additionally the Arrowhead\u00a0licensing deal\u00a0bringing an RNA angle into the\u00a0Novartis neuroscience pipeline. The corporate licensed ARO-SNCA, a preclinical siRNA remedy designed to scale back alpha-synuclein, with Novartis gaining world rights in a deal value as much as $2 billion. The goal locations this system in synucleinopathies, together with Parkinson\u2019s illness, however strategically the deal additionally provides Novartis one other route into RNA-based neuroscience.\u00a0<\/p>\n
Novartis additionally appeared into supply with BioArctic. The collaboration\u00a0combines\u00a0BioArctic\u2019s BrainTransporter expertise with\u00a0a Novartis proprietary antibody, with the goal of producing a drug candidate for extreme neurological circumstances. BioArctic stated Novartis would take over world growth and commercialization if it workouts its choice.\u00a0<\/p>\n
Novartis immunology technique: defending Cosentyx whereas shifting into new mechanisms\u00a0<\/h3>\n
Immunology is one other space the place the technique combines lifecycle administration with new mechanisms.\u00a0<\/p>\n
Cosentyx\u00a0stays\u00a0the established franchise with\u00a0$6.67 billion\u00a0in gross sales in 2025, making it Novartis\u2019 second-largest drugs after Entresto. However Novartis can be making an attempt to broaden immunology past the IL-17 franchise.\u00a0<\/p>\n
The FDA\u00a0accepted\u00a0Rhapsido in September 2025 for power spontaneous urticaria in sufferers who stay symptomatic after antihistamines.\u00a0The drug is\u00a0an oral focused BTK inhibitor, with a security profile that requires no lab\u00a0monitoring\u00a0in line with Novartis. The European Fee approval adopted in April 2026.\u00a0<\/p>\n
The\u00a0Monte Rosa deal\u00a0is an earlier-stage, extra platform-driven immunology technique.\u00a0Novartis and Monte Rosa expanded their collaboration in 2025 to develop molecular glue degraders for immune-mediated ailments, following an earlier settlement round VAV1 degraders together with MRT-6160. Monte Rosa stated the collaboration is meant to speed up degrader growth in opposition to difficult-to-drug immune targets.\u00a0<\/p>\n
Novartis is doing greater than changing one blockbuster with one other. It’s investing in applied sciences that might generate a number of merchandise throughout its therapeutic areas. Radioligand remedy extends past\u00a0Pluvicto\u00a0by way of the Mariana acquisition, whereas current offers in RNA therapeutics, protein degradation and drug supply present capabilities that might assist future packages. Novartis itself describes\u00a0xRNA, radioligand remedy, and gene and cell remedy as superior expertise platforms supposed to supply sustained scalability throughout its pipeline.\u00a0\u00a0<\/p>\n
By concentrating sources on 4 therapeutic areas, Novartis can deepen scientific\u00a0experience, simplify capital\u00a0allocation\u00a0and strengthen positions in applied sciences the place manufacturing\u00a0know-how\u00a0and specialised infrastructure\u00a0are\u00a0aggressive benefits. That is notably the case in radioligand remedy, the place success relies upon additionally on securing isotope provide, manufacturing\u00a0capability\u00a0and therapy networks. In its 2025 annual report, Novartis highlighted continued funding in increasing its radioligand manufacturing footprint and supply community to assist future progress.\u00a0<\/p>\n
A extra centered firm, nevertheless, additionally turns into extra depending on the success of its chosen applied sciences. Lots of Novartis\u2019 current acquisitions stay in scientific growth, whereas newer modalities reminiscent of RNA therapeutics and focused protein degradation have but to supply giant numbers of economic medicines. The corporate has lowered the complexity of its portfolio, however in doing so it has concentrated execution threat round a smaller variety of bets. The subsequent problem is proving {that a} extra centered Novartis can be a extra resilient one.\u00a0<\/p>\n<\/div>\n
\n
Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Novartis\u2019 present technique could be traced again to\u00a0October 2023, when the Swiss pharma accomplished the spin-off of Sandoz, its generics and biosimilars enterprise. The corporate\u00a0described\u00a0the transfer because the completion of a strategic transformation\u00a0into\u00a0a centered modern medicines firm,\u00a0whereas chief govt officer (CEO) Vas Narasimhan\u00a0stated it allowed Novartis to \u201cabsolutely deal with high-value modern medicines.\u201d\u00a0 Novartis says […]<\/p>\n","protected":false},"author":1,"featured_media":1849,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/paul-skorupskas-7KLa-xLbSXA-unsplash.jpg","fifu_image_alt":"","jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_override_bookmark_settings":[],"jnews_social_meta":[],"jnews_override_counter":[],"footnotes":""},"categories":[10],"tags":[2342,1139,28],"class_list":["post-1847","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology","tag-novartis","tag-pipeline","tag-strategy"],"yoast_head":"\n
Novartis' pipeline technique in 2026 - Future News 24<\/title>\n<meta name=\"description\" content=\"Find out what Novartis' pipeline strategy since it spun off its biosimilars and generics business Sandoz, and engage in intensive dealmaking.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/futurenews24.com\/index.php\/2026\/07\/03\/novartis-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis' pipeline technique in 2026 - Future News 24\" \/>\n<meta property=\"og:description\" content=\"Find out what Novartis' pipeline strategy since it spun off its biosimilars and generics business Sandoz, and engage in intensive dealmaking.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/futurenews24.com\/index.php\/2026\/07\/03\/novartis-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"Future News 24\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-03T13:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-04T02:59:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/paul-skorupskas-7KLa-xLbSXA-unsplash.jpg\" \/>\n<meta name=\"author\" content=\"Future News 24\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/paul-skorupskas-7KLa-xLbSXA-unsplash.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Future News 24\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/03\\\/novartis-pipeline\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/03\\\/novartis-pipeline\\\/\"},\"author\":{\"name\":\"Future News 24\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/person\\\/cecad1bde21cfc357cf70128144d6c83\"},\"headline\":\"Novartis’ pipeline technique in 2026\",\"datePublished\":\"2026-07-03T13:00:00+00:00\",\"dateModified\":\"2026-07-04T02:59:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/03\\\/novartis-pipeline\\\/\"},\"wordCount\":1835,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/03\\\/novartis-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.labiotech.eu\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/paul-skorupskas-7KLa-xLbSXA-unsplash.jpg\",\"keywords\":[\"Novartis\",\"pipeline\",\"Strategy\"],\"articleSection\":[\"BioTechnology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/03\\\/novartis-pipeline\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/03\\\/novartis-pipeline\\\/\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/03\\\/novartis-pipeline\\\/\",\"name\":\"Novartis' pipeline technique in 2026 - Future News 24\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/03\\\/novartis-pipeline\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/03\\\/novartis-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.labiotech.eu\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/paul-skorupskas-7KLa-xLbSXA-unsplash.jpg\",\"datePublished\":\"2026-07-03T13:00:00+00:00\",\"dateModified\":\"2026-07-04T02:59:07+00:00\",\"description\":\"Find out what Novartis' pipeline strategy since it spun off its biosimilars and generics business Sandoz, and engage in intensive dealmaking.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/03\\\/novartis-pipeline\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/03\\\/novartis-pipeline\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/03\\\/novartis-pipeline\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.labiotech.eu\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/paul-skorupskas-7KLa-xLbSXA-unsplash.jpg\",\"contentUrl\":\"https:\\\/\\\/www.labiotech.eu\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/paul-skorupskas-7KLa-xLbSXA-unsplash.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/07\\\/03\\\/novartis-pipeline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/futurenews24.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novartis’ pipeline technique in 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#website\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/\",\"name\":\"Future News 24\",\"description\":\"The Smart Hub for AI and Next-Gen Innovation\",\"publisher\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/futurenews24.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\",\"name\":\"Future News 24\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/fn24-favicon.png\",\"contentUrl\":\"https:\\\/\\\/futurenews24.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/fn24-favicon.png\",\"width\":250,\"height\":250,\"caption\":\"Future News 24\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/person\\\/cecad1bde21cfc357cf70128144d6c83\",\"name\":\"Future News 24\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"caption\":\"Future News 24\"},\"sameAs\":[\"https:\\\/\\\/futurenews24.com\"],\"url\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/author\\\/mridulpahuja20\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novartis' pipeline technique in 2026 - Future News 24","description":"Find out what Novartis' pipeline strategy since it spun off its biosimilars and generics business Sandoz, and engage in intensive dealmaking.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/futurenews24.com\/index.php\/2026\/07\/03\/novartis-pipeline\/","og_locale":"en_US","og_type":"article","og_title":"Novartis' pipeline technique in 2026 - Future News 24","og_description":"Find out what Novartis' pipeline strategy since it spun off its biosimilars and generics business Sandoz, and engage in intensive dealmaking.","og_url":"https:\/\/futurenews24.com\/index.php\/2026\/07\/03\/novartis-pipeline\/","og_site_name":"Future News 24","article_published_time":"2026-07-03T13:00:00+00:00","article_modified_time":"2026-07-04T02:59:07+00:00","og_image":[{"url":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/paul-skorupskas-7KLa-xLbSXA-unsplash.jpg","type":"","width":"","height":""}],"author":"Future News 24","twitter_card":"summary_large_image","twitter_image":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/paul-skorupskas-7KLa-xLbSXA-unsplash.jpg","twitter_misc":{"Written by":"Future News 24","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/03\/novartis-pipeline\/#article","isPartOf":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/03\/novartis-pipeline\/"},"author":{"name":"Future News 24","@id":"https:\/\/futurenews24.com\/#\/schema\/person\/cecad1bde21cfc357cf70128144d6c83"},"headline":"Novartis’ pipeline technique in 2026","datePublished":"2026-07-03T13:00:00+00:00","dateModified":"2026-07-04T02:59:07+00:00","mainEntityOfPage":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/03\/novartis-pipeline\/"},"wordCount":1835,"commentCount":0,"publisher":{"@id":"https:\/\/futurenews24.com\/#organization"},"image":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/03\/novartis-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/paul-skorupskas-7KLa-xLbSXA-unsplash.jpg","keywords":["Novartis","pipeline","Strategy"],"articleSection":["BioTechnology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/futurenews24.com\/index.php\/2026\/07\/03\/novartis-pipeline\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/03\/novartis-pipeline\/","url":"https:\/\/futurenews24.com\/index.php\/2026\/07\/03\/novartis-pipeline\/","name":"Novartis' pipeline technique in 2026 - Future News 24","isPartOf":{"@id":"https:\/\/futurenews24.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/03\/novartis-pipeline\/#primaryimage"},"image":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/03\/novartis-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/paul-skorupskas-7KLa-xLbSXA-unsplash.jpg","datePublished":"2026-07-03T13:00:00+00:00","dateModified":"2026-07-04T02:59:07+00:00","description":"Find out what Novartis' pipeline strategy since it spun off its biosimilars and generics business Sandoz, and engage in intensive dealmaking.","breadcrumb":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/03\/novartis-pipeline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/futurenews24.com\/index.php\/2026\/07\/03\/novartis-pipeline\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/03\/novartis-pipeline\/#primaryimage","url":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/paul-skorupskas-7KLa-xLbSXA-unsplash.jpg","contentUrl":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/07\/paul-skorupskas-7KLa-xLbSXA-unsplash.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/futurenews24.com\/index.php\/2026\/07\/03\/novartis-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/futurenews24.com\/"},{"@type":"ListItem","position":2,"name":"Novartis’ pipeline technique in 2026"}]},{"@type":"WebSite","@id":"https:\/\/futurenews24.com\/#website","url":"https:\/\/futurenews24.com\/","name":"Future News 24","description":"The Smart Hub for AI and Next-Gen Innovation","publisher":{"@id":"https:\/\/futurenews24.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/futurenews24.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/futurenews24.com\/#organization","name":"Future News 24","url":"https:\/\/futurenews24.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/futurenews24.com\/#\/schema\/logo\/image\/","url":"https:\/\/futurenews24.com\/wp-content\/uploads\/2026\/06\/fn24-favicon.png","contentUrl":"https:\/\/futurenews24.com\/wp-content\/uploads\/2026\/06\/fn24-favicon.png","width":250,"height":250,"caption":"Future News 24"},"image":{"@id":"https:\/\/futurenews24.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/futurenews24.com\/#\/schema\/person\/cecad1bde21cfc357cf70128144d6c83","name":"Future News 24","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","caption":"Future News 24"},"sameAs":["https:\/\/futurenews24.com"],"url":"https:\/\/futurenews24.com\/index.php\/author\/mridulpahuja20\/"}]}},"_links":{"self":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/1847","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/comments?post=1847"}],"version-history":[{"count":1,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/1847\/revisions"}],"predecessor-version":[{"id":1848,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/1847\/revisions\/1848"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/media\/1849"}],"wp:attachment":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/media?parent=1847"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/categories?post=1847"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/tags?post=1847"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}